Overall, 8 of 17 (47%) of ER-low or negative, HER2– patients whose tumors were PDX+ died of breast cancer, whereas only 1 of 45 (2.2%) of PDX– patients have died of breast cancer. Here, ERBB2 is linked to breast carcinoma.